CareDx (NASDAQ:CDNA) Hits New 52-Week High – Time to Buy?

Posted by George Bondi on Oct 7th, 2026

CareDx, Inc. (NASDAQ:CDNA – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Monday. The stock traded as high as $69.95 and last traded at $69.5130, with a volume of 488926 shares traded. The stock had previously closed at $67.15.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on CDNA shares. HC Wainwright reissued a “neutral” rating and set a $46.00 price objective on shares of CareDx in a research note on Friday, July 31st. Zacks Research cut CareDx from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. Craig Hallum raised CareDx from a “hold” rating to a “buy” rating and set a $64.00 price target on the stock in a research note on Monday, August 3rd. William Blair upgraded CareDx to a “hold” rating in a report on Thursday, July 16th. Finally, Canaccord Genuity Group began coverage on CareDx in a research note on Wednesday, September 2nd. They issued a “buy” rating and a $65.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $54.00.

Read Our Latest Research Report on CDNA

CareDx Price Performance

The business has a 50-day moving average of $51.76 and a 200-day moving average of $33.64. The firm has a market cap of $3.30 billion, a price-to-earnings ratio of 30.82 and a beta of 2.38.

CareDx (NASDAQ:CDNA – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.23 by $0.14. The firm had revenue of $131.95 million during the quarter, compared to analysts’ expectations of $114.05 million. CareDx had a return on equity of 2.87% and a net margin of 24.23%.The business’s quarterly revenue was up 52.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.16) earnings per share. As a group, equities analysts anticipate that CareDx, Inc. will post 0.47 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director George Bickerstaff, III sold 20,000 shares of CareDx stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $46.28, for a total transaction of $925,600.00. Following the completion of the transaction, the director directly owned 134,061 shares in the company, valued at approximately $6,204,343.08. The trade was a 12.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Christine Cournoyer sold 16,000 shares of CareDx stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $46.94, for a total value of $751,040.00. Following the transaction, the director owned 42,943 shares of the company’s stock, valued at $2,015,744.42. This represents a 27.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On CareDx

Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in shares of CareDx during the 2nd quarter worth about $137,219,000. Bamco Inc. NY acquired a new stake in CareDx during the second quarter worth approximately $55,214,000. Gagnon Securities LLC boosted its holdings in shares of CareDx by 2.6% during the fourth quarter. Gagnon Securities LLC now owns 1,774,890 shares of the company’s stock worth $33,439,000 after acquiring an additional 45,465 shares during the period. Amova Asset Management Americas Inc. boosted its holdings in shares of CareDx by 2.0% during the first quarter. Amova Asset Management Americas Inc. now owns 1,475,126 shares of the company’s stock worth $25,608,000 after acquiring an additional 28,510 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in shares of CareDx by 2.0% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,475,126 shares of the company’s stock worth $25,608,000 after purchasing an additional 28,510 shares during the period.

CareDx Company Profile

(Get Free Report)

CareDx, Inc (NASDAQ: CDNA) is a precision-medicine company focused on improving the care of organ-transplant patients. The company develops diagnostic tests, digital tools and services designed to help clinicians monitor transplant recipients, assess the risk of rejection and support long-term graft management.

CareDx’s product portfolio includes AlloMap, a gene-expression blood test used in heart-transplant surveillance, and AlloSure, a donor-derived cell-free DNA test designed to help detect potential organ injury or rejection.